Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:alsoKnownAs |
Imvamune
Imvanex |
| gptkbp:approvedBy |
gptkb:Canada
gptkb:European_Union gptkb:United_States gptkb:U.S._Food_and_Drug_Administration 2019 prevention of monkeypox prevention of smallpox |
| gptkbp:compatibleWith |
replication in human cells
|
| gptkbp:contains |
Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
|
| gptkbp:developedBy |
Bavarian Nordic
|
| gptkbp:dosingSchedule |
two doses, 28 days apart
|
| gptkbp:excludes |
replicating virus
|
| https://www.w3.org/2000/01/rdf-schema#label |
JYNNEOS vaccine
|
| gptkbp:indication |
adults 18 years and older
|
| gptkbp:marketedAs |
Bavarian Nordic
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:safetyProfile |
well-tolerated
|
| gptkbp:sideEffect |
fatigue
headache muscle pain injection site reactions |
| gptkbp:storage |
-20°C
|
| gptkbp:type |
non-replicating live attenuated vaccine
|
| gptkbp:usedDuring |
2022 monkeypox outbreak
|
| gptkbp:usedFor |
post-exposure prophylaxis
pre-exposure prophylaxis |
| gptkbp:WHOPrequalified |
no
|
| gptkbp:bfsParent |
gptkb:mpox
|
| gptkbp:bfsLayer |
7
|